Ahmedabad-based CRO Veeda Clinical Research, launched a new division, called Global Oncology CRO, to concentrate on cancer research while leveraging Veeda’s operational capacities in the United States, Europe and India. The oncology subsidiary will be led by its president and chief executive officer, Matt Bowman. The new business will be headquartered in Columbus, Ohio. Kathy Squillace was named to the position of vice president of clinical operations and Dave Colborn was made vice president of data management and information technology.

“Since July 1, 2007 we have been establishing the infrastructure for a global oncology CRO and today we are pleased to announce that both the personnel and technical infrastructure are in place, validated and tested,” said Binoy Gardi, Group Managing Director, Veeda Clinical Research. 

The company stated it expects to expand its global capacity with targeted acquisitions in the coming months. Veeda bought a 40-bed phase I facility in Gorlitz, Germany last May. The facility is located in eastern Germany on the border of Poland and the Czech Republic. The unit was established in 1992 and has 15 staff.

Veeda was created in 2005 from the merger of the 18-year-old UK-based CRO, Phase I Clinical Trials Unit and two-year-old Clinsearch, an India-based phase I unit founded by Binoy Gardi and Apurva Shah.

In December 2006, Veeda acquired DICE, a Brussels-based CRO founded in 1989. The firm focused on data management, biostatistics and medical writing and provided Veeda with a European presence outside the United Kingdom.